Inflammation imaging to define vulnerable plaque or vulnerable patient

Area of Science:

• Cardiovascular Imaging
• Nuclear Medicine
• Molecular Imaging

Background:

• High-risk atherosclerotic plaques pose a significant clinical challenge.
• Nuclear imaging offers high sensitivity for detecting radiopharmaceutical signals in tissues.
• Inflammation is a key factor in plaque vulnerability.

Purpose of the Study:

• To review the insights provided by [18F]FDG PET in understanding plaque inflammation.
• To explore the role of inflammation in defining vulnerable plaques and patients.
• To discuss alternative radiopharmaceuticals for plaque imaging.

Main Methods:

• Review of studies utilizing [18F]FDG PET for atherosclerotic plaque imaging.
• Analysis of [18F]FDG PET's ability to detect and quantify plaque inflammation.
• Discussion of alternative radiopharmaceuticals and imaging targets.

Main Results:

• [18F]FDG PET is the most studied radiopharmaceutical for molecular imaging of atherosclerotic plaques.
• [18F]FDG PET effectively detects, monitors, and quantifies inflammatory processes in plaques.
• The technique contributes to understanding plaque vulnerability and patient risk.

Conclusions:

• [18F]FDG PET is a valuable tool for characterizing high-risk atherosclerotic plaques.
• Inflammation plays a crucial role in plaque vulnerability, as highlighted by [18F]FDG PET insights.
• Further research into alternative radiopharmaceuticals is warranted for comprehensive plaque assessment.